Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Armed With CXCR4 Antagonist for Treatment of Ovarian Cancer Abstract Buffalo, NY based Tactiva Therapeutics, Inc. announced they’ve licensed new intellectual property from the Roswell Park Cancer Institute Corporation that covers the use of the Oncolytic Vaccinia Virus (OVV) ... Read More
